Protocol for the Arterial Revascularisation Trial (ART). A randomised trial to compare survival following bilateral versus single internal mammary grafting in coronary revascularisation [ISRCTN46552265] by Taggart, David P et al.
BioMed  Central
Page 1 of 11
(page number not for citation purposes)
Trials
Open Access Study protocol
Protocol for the Arterial Revascularisation Trial (ART). A 
randomised trial to compare survival following bilateral versus 
single internal mammary grafting in coronary revascularisation 
[ISRCTN46552265]
David P Taggart*1, Belinda Lees2, Alastair Gray3, Douglas G Altman4, 
Marcus Flather2, Keith Channon5 and the ART Investigators
Address: 1Nuffield Dept of Surgery, University of Oxford, John Radcliffe Hospital, Oxford, OX3 9DU, UK, 2Clinical Trials and Evaluation Unit, 
Royal Brompton and Harefield NHS Trust, Sydney Street, London SW3 6NP, UK, 3Health Economics Research Centre, Institute of Health Sciences, 
Oxford OX3 7LF, UK, 4Cancer Research UK Medical Statistics Group, Centre for Statistics in Medicine, Wolfson College, University of Oxford, 
Linton Road, Oxford OX2 6UD, UK and 5Department of Cardiovascular Medicine, John Radcliffe Hospital, Headington, Oxford OX3 9DU, UK
Email: David P Taggart* - david.taggart@orh.nhs.uk; Belinda Lees - b.lees@rbh.nthames.nhs.uk; Alastair Gray - alastair.gray@dphpc.ox.ac.uk; 
Douglas G Altman - doug.altman@cancer.org.uk; Marcus Flather - m.flather@rbh.nthames.nhs.uk; 
Keith Channon - keith.channon@cardiov.ox.ac.uk; the ART Investigators - b.lees@rbh.nthames.nhs.uk
* Corresponding author    
Abstract
Background: Standard coronary artery bypass graft surgery uses a single internal mammary artery
and supplemental vein or radial artery grafts. Several observational studies have suggested a survival
benefit with two internal mammary artery grafts compared to a single internal mammary artery
graft, but this has not been tested in a randomised trial. The Arterial Revascularisation Trial is a
Medical Research Council and British Heart Foundation funded, multi-centre international trial
comparing single internal mammary artery grafting versus bilateral internal mammary artery
grafting.
Methods/Design:  Twenty centres in the UK, Australia, Poland and Brazil are planning to
randomise 3000 coronary artery bypass graft surgery patients to single or bilateral internal
mammary artery grafting. Supplemental grafts may be either saphenous vein or radial artery.
Coronary artery bypass grafting can be performed as an on-pump or off-pump procedure. The
primary outcome is survival at 10 years and secondary end-points include clinical events, quality of
life and cost effectiveness. The effect of age, left ventricular function, diabetes, number of grafts,
vein grafts and off-pump surgery are pre-specified subgroups.
Discussion: The Arterial Revascularisation Trial is one of the first randomised trials to evaluate
the effects on survival and other clinical outcomes of single internal mammary artery grafting versus
bilateral internal mammary artery grafting, and will help to establish the best approach for patients
requiring coronary artery bypass graft surgery.
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Background
Coronary artery bypass graft (CABG) surgery is the opti-
mal therapy, prognostically and symptomatically, for
multi-vessel ischaemic heart disease [1]. Worldwide,
around 800,000 CABG are performed annually. Recognis-
ing the under provision of CABG in the UK, the National
Service Framework (NSF) aims to increase numbers from
500 [2] to 750 per million of population. The require-
ment for CABG is also likely to increase because of a grow-
ing elderly population with coronary disease and because
percutaneous interventions ultimately lead to an
increased requirement for CABG [3].
Most CABG patients require three grafts and the standard
operation uses a single internal mammary artery (SIMA)
and supplemental vein or radial artery grafts (Figure 1).
CABG provides excellent short and intermediate term out-
comes but its long-term efficacy is limited by vein graft
failure. Ten years after CABG around 1/2 of vein grafts are
blocked and of the remaining 50% half are severely dis-
eased [6] whereas up to 95% of internal mammary artery
(IMA) conduits remain disease free. In addition to reduc-
ing long-term survival, vein graft failure significantly
increases the risk of recurrent angina, late myocardial inf-
arction and the need for further intervention [4-7].
Indeed, by 10 years after CABG >50% of patients have
recurrent angina and up to 1/3 may eventually require
redo CABG [8-11]. Aspirin and statins [10,11] may
improve vein graft patency but are unlikely to achieve the
patency rates of IMA grafts.
As discussed below, bilateral IMA (BIMA) in comparison
to SIMA grafts, may improve survival and reduce the need
for redo CABG. However while BIMA grafting is common
Schematic drawing showing typical examples of: (1) Single internal mammary artery (SIMA) grafts and (2–4) Bilateral internal  mammary artery (BIMA) grafts Figure 1
Schematic drawing showing typical examples of: (1) Single internal mammary artery (SIMA) grafts and (2–4) Bilateral internal 
mammary artery (BIMA) grafts. Key: IMA = internal mammary artery; RA = radial artery; SVG = saphenous vein graft.
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in some centres in Europe, America, Australia and Japan,
it still not widely used. For example, in 1998 15% of UK
CABG patients received two arterial grafts (and a signifi-
cant proportion of these would have used a radial artery
rather than a second IMA graft) [2]. The major reasons for
not using BIMA grafts is because of no definitive evidence
of benefits (there are no randomised trials) and the per-
ceptions that it is technically more challenging, more pro-
longed and increases the risk of impaired wound healing.
Given the number of CABG procedures currently per-
formed in the UK and the aim of the NSF to increase these
numbers, it is also important to obtain accurate informa-
tion on the costs and cost-effectiveness of using BIMA ver-
sus SIMA grafts.
Nine studies, reviewed extensively in reference 12, have
compared the influence of SIMA and BIMA grafts on sur-
vival and the need for redo surgery. Interpretation of indi-
vidual studies is, however, complicated by lack of
randomisation, small patient numbers and inadequate
length or completeness of follow-up. Furthermore, as the
use of BIMA grafts was initially confined to younger, lower
risk patients, any long-term benefits were attributed to the
inherently more favourable characteristics of these
patients, obscuring any benefit of BIMA.
A recent systematic review was performed of those studies,
meeting pre-specified criteria relating to patient selection,
comparability of groups, outcome assessment, and com-
pleteness of follow-up, to determine if there are differ-
ences in survival, expressed as a pooled hazard ratio (HR),
in patients receiving SIMA or BIMA [12] (Figure 2). The
analysis included 15962 patients comprising 11269 SIMA
and 4693 BIMA patients from seven studies that either
matched or adjusted for age, sex, ventricular function and
diabetes. The results suggested a survival advantage for
BIMA grafts (HR for death = 0.81, 95%CI: 0.70 to 0.94)
without any evidence of a detrimental effect, however
there was very limited evidence relating to secondary end-
points including possible adverse consequences.
In the largest single study [13], of 8000 SIMA and 2000
BIMA patients, Lytle et al reported that the HR for death
was decreased by 23% in the BIMA group at 12 years and
the need for redo CABG reduced from 40% in the SIMA to
10% in the BIMA group.
In another observational study, published after the sys-
tematic review, Endo et al reported outcome in 688 SIMA
and 443 BIMA patients [14]. The groups were similar
regarding age and ventricular function but there were
more diabetics in the BIMA group (18% vs 13%) and
females in the SIMA group (19% vs 10%). At six years the
combined incidence of death, myocardial infarction and
redo CABG was lower in the BIMA group (p = 0.06) and
particularly in the 782 patients below 71 years and with
an ejection fraction > 0.4 (HR: 0.61; 95%CI, 0.38 to
0.98:p = 0.04). As vein graft failure increases markedly
beyond seven years after CABG the authors suggest that
the benefits of BIMA grafts are likely to increase with fur-
ther follow-up.
Two studies reported no benefit of BIMA grafting [15,16].
Sergeant's study, however, had fewer than 100 BIMA
patients with 10-year follow up and use of the second IMA
was frequently suboptimal [15]. Kurlansky et al reported
no survival difference at ten years in 261 women with
BIMA grafts and a matched cohort with SIMA grafts [16].
However, 81% of the BIMA group vs 66% of the SIMA
group had triple vessel disease (p < 0.001) and only 120
patients in each group were available for comparison at
ten years.
For optimal patency both IMA should be placed to the left
sided arteries [17-19] (Figure 1). Patency of the right IMA
is reduced if used as a free aortic graft [18] or placed to the
right coronary artery [19] due to size discrepancy and
eventual disease development at the crux.
Angiographic studies demonstrate markedly superior pat-
ency of BIMA grafts, compared to vein grafts, refuting the
assertion that the superior patency of IMA grafts is due to
better 'run-off' in the LAD territory. Patency rates for BIMA
to various coronary arteries, are 98% at 7 days [14] and
95% at two [20] and seven years [21]. Furthermore, off-
pump CABG (OPCAB) now makes CABG feasible in
patients whose advanced age previously precluded CABG
using cardiopulmonary bypass. A composite radial artery
from one or both IMA, allows up to four grafts as an 'off-
pump' CABG, eliminating both cardiopulmonary bypass
Survival following bilateral internal mammary artery (IMA)  grafting compared to single IMA grafting [12] Figure 2
Survival following bilateral internal mammary artery (IMA) 
grafting compared to single IMA grafting [12].
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Effect of BIMA compared with SIMA
Weight
% (95% CI)
Hazard ratio
Favours
SIMA BIMA
Favours
Hazard ratio
1.21 (0.84 to 1.73)  Morris (1990)  13.2
0.75 (0.45 to 1.26)  Naunheim (1992)   7.2
1.01 (0.58 to 1.72)  Dewar (1995)   6.5
0.50 (0.18 to 1.40)  Berreklouw (1995)   2.0
0.82 (0.50 to 1.33)  Pick (1997)   7.9
0.71 (0.56 to 0.91)  Buxton (1998)  22.8
0.77 (0.66 to 0.89)  Lytle (1999)  40.4
0.81 (0.70 to 0.94)  Overall (95% CI)Trials 2006, 7:7 http://www.trialsjournal.com/content/7/1/7
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and aortic manipulation and minimizing the risk of cere-
bral injury [22].
Opposition to BIMA grafting is largely based on the per-
ception of increased perioperative risk and especially ster-
nal wound morbidity. There is consistent evidence,
however, that the operative mortality of BIMA grafting at
1%–2% [12,13] is no higher, and may, in fact, be less than
that of the standard operation because of a reduced risk of
early graft failure.
Sternal dehiscence is a potential complication of BIMA
grafts and particularly in diabetics. In reality, there is only
a minimal increase in the risk of impaired wound healing
in both non-diabetics [13,23-27] and diabetics [23-27]
unless the patient is morbidly obese and/or has marked
respiratory impairment [24]. The risk of impaired wound
healing can be minimized with judicious patient selection
and modification of the IMA harvesting method whereby
a 'skeletonized' rather than 'pedicled' fashion preserves
collaterals and sternal blood supply [25] and improves
wound healing, particularly in diabetics. No difference
has been found in myocardial enzymes [28], parameters
of respiratory exchange [29] or in respiratory injury
between SIMA and BIMA patients. BIMA harvesting adds
around 30 minutes to a three-hour operation.
Uncertainty remains because there is no randomised evi-
dence, therefore a randomised trial – the Arterial Revascu-
larisation Trial (ART) – has been designed to compare
SIMA versus BIMA grafting in coronary revascularisation.
ART will compare survival rates, need for redo CABG,
other clinical events, quality of life and cost effectiveness
of SIMA versus BIMA grafting.
The main objective of ART is to assess whether the use of
both IMA during CABG (BIMA) improves survival and
reduces the need for further interventions over that
observed with a single IMA (SIMA).
Methods/Design
Trial design
Two-arm, randomised multi-centre trial. Patients will be
randomised to SIMA or BIMA with supplemental vein or
radial artery grafts as required.
Eligibility
Inclusion criteria
• CABG patients with multi-vessel coronary artery disease
(including urgent and off pump CABG patients)
Exclusion criteria
• Single graft
• Redo CABG
• Evolving myocardial infarction
• Concomitant valve surgery
Randomisation and enrolment process
All patients requiring CABG should be considered for
entry into the study. Centres should keep a screening log
and record if the patient is entered into the study and if
not the reason why not. Patients who meet the eligibility
criteria and give written informed consent should be ran-
domised.
Randomisation will be performed by telephone contact
with the trial co-ordinating centre (the Clinical Trials and
Evaluation Unit (CTEU) based at the Royal Brompton
Hospital in London). The randomisation service will be
available 09:00–17:00 (UK time). Centres will be asked
for a few simple details about the patient including ini-
tials, date of birth and eligibility criteria. The caller will be
given the procedure allocation (SIMA or BIMA) and a fax
will be sent to the centre confirming this.
Eligible patients will be randomised in equal proportions
between the two surgical strategies SIMA or BIMA. The
allocated procedure will be performed by a trial nomi-
nated surgeon who has been approved by the Trial Steer-
ing Committee as being sufficiently experienced (ie.
performed >50 BIMA procedures).
Randomisation will be stratified by centre with specific
tables using block allocation to provide treatment distri-
bution in equal proportions. The block size will itself be
subject to random variation.
To reduce the possibility of outcome measure events
occurring after randomisation and before revascularisa-
tion, surgery should be performed within 6 weeks of ran-
domisation.
Surgical procedure
It is left to the individual centres to decide the optimal
anaesthetic technique and method of myocardial protec-
tion for each patient. As there is a consistent mortality of
around 2.5% for CABG across most UK centres this sug-
gests that minor differences in anaesthetic technique and
methods of myocardial protection do not have a major
influence on perioperative mortality. Surgical details will
be recorded in the case report form (CRF). The only
requirement is that the surgeon follows the randomisa-
tion allocation given for the patient (ie. SIMA or BIMA).
Surgery can be performed with cardiopulmonary bypass
or as an off-pump procedure according to the experience
of the surgeon.Trials 2006, 7:7 http://www.trialsjournal.com/content/7/1/7
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The following surgical procedures should be applied
depending on the allocation to SIMA or BIMA:-
SIMA – standard operation using SIMA to LAD plus sup-
plemental vein or radial artery graft
BIMA – both IMA placed to left sided coronary arteries
with supplemental vein or radial artery. The IMA grafts
can be used as composite grafts to each other, as long as
one remains in situ.
Possible combinations include
• LIMA to OM and RIMA to LAD
• LIMA to LAD and RIMA to OM (via transverse sinus)
• LIMA to LAD and RIMA as composite graft to OM
Some typical examples of SIMA and BIMA grafts are
shown in Figure 1.
Please note that anastomosis of an IMA graft to the right
coronary artery is an exclusion criteria (because of evi-
dence of inferior long-term patency).
Outcome measures
Primary
• Death from any cause (cardiovascular and non-cardio-
vascular mortality).
This outcome will be recorded using the flagging system of the
Office of National Statistics (using name, address, date of birth
and NHS number).
Secondary
Secondary clinical outcome measures will be assessed in a
blinded fashion by the Clinical Events Review Committee.
These outcomes will be measured in hospital, at routine 6-week
clinical follow-up and from telephone questionnaires. Out-
comes are as follows:-
a. Cause-specific death
• Death will be classified into cardiac, other vascular and
non-cardiovascular, where possible, using autopsy reports
and death certificates. Death will also be classified by ICD
code.
• Death due to cardiac causes: Cardiac causes of death such
as congestive heart failure, arrhythmia or myocardial infarc-
tion.
• Other vascular causes of death: Vascular causes of death
such as pulmonary embolus, dissection, cerebrovascular acci-
dent or bleeding event.
• Non-cardiovascular causes of death: This includes any other
cause of death.
b. 30 day mortality
• Death from any cause by 30 days post surgery
• Cause-specific death by 30 days post surgery
c. 90 day mortality
• Death from any cause by 90 days post surgery
• Cause-specific death by 90 days post surgery
d. Need for re-intervention
ie percutaneous coronary intervention or redo surgery
e. Other clinical events
• Myocardial infarction, major bleeding, cerebrovascular
accident and other serious adverse events will be captured.
f. Quality of Life and cost effectiveness evaluation
• These outcomes will be measured from questionnaires
(Rose -shortened form, EuroQol-5D, SF36 and Health
Services Resource use). These outcomes will be assessed
blind to the knowledge of which arm the trial the patient
is in.
Follow-up
A summary of the follow up is shown in Table 1.
Annual Quality of Life questionnaires (Table 2) will be
sent to study participants by post, no clinic visits are
required apart from the routine clinical 6-week post oper-
ative visit. Participants will be sent stamped addressed
envelopes to improve the return rates of postal question-
naires. Study co-ordinators will telephone participants to
alert them to the questionnaires arrival and to ask them
about medications, adverse events and health services
resource use.
Health service research issues
Information will be collected in each centre on resources
used during the hospital stay, time in operating theatre,
total blood and coagulant product use, time in cardiac
recovery unit, days on ward; treatment of complications
(eg return to theatre), drugs prescribed at hospital dis-
charge, use of cardiac rehabilitation.
Information on subsequent in-patient episodes (includ-
ing interventions and duration) on outpatient visits and
diagnostic procedures, and on general practitioner and
practice nurse consultations will be obtained from the
patient during the annual telephone call. This call will
also ask about specified medications (eg aspirin, statins,
ace-inhibitors, beta-blockers, calcium channel antago-Trials 2006, 7:7 http://www.trialsjournal.com/content/7/1/7
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nists). Participating centres will also record and report
subsequent rehospitalisations and revascularisations of
patients in the trial.
Trial size
Number of patients
To achieve an absolute 5% reduction in 10-year mortality
(ie from 25% to 20%), with 90% power at 5% alpha
requires 2928 patients. The mortality data is taken from a
summary of previous studies published in reference 12.
The aim is to enrol at least 3000 patients (1500 in each
arm) over a 2 to 3 year recruitment period in 20 centres in
the UK, Australia, Poland and Brazil (Table 3). As the
intervention is the operation, compliance is likely to be
100% except in the unusual situation where the planned
operation is not possible for technical reasons.
Loss to follow-up
• For the primary outcome (ie death of trial patients) there
should be minimal loss as patient death will be automat-
ically flagged via the Office of National Statistics
• For secondary outcome measures around 5% of patients
may be lost to follow-up due to non-compliance with
questionnaires or movement to other areas. Study co-
ordinators at each centre will maintain telephone contact
with participants to record Health Service Resource Use,
to record adverse events, to alert them of the question-
naires' arrival, to ensure addresses are current and to fol-
low-up any non-responders.
Statistical issues
Type of analyses
The trial data will be analysed on an intention-to-treat
basis with patients included in the groups assigned at ran-
domisation, irrespective of future management and
events. Outcome measure event tracking will begin at ran-
domisation and continue until death or the end of follow-
up. Analysis of time to event data will use log rank tests
and possibly other methods suitable for survival data, in
particular to take account of known prognostic variables.
Frequency of analyses
A limited number of interim analyses will be performed
by the trial statistician as specified by the Data Monitoring
Committee (DMC). The accumulating results will not be
available to the trialists or other principal investigators.
The final, definitive analysis of the trial data will be con-
ducted 120 months after the date of commencement of
the trial.
Analyses of cost-effectiveness and quality of life data
Overall analysis will be performed from the perspective of
the health care system; basic information will also be col-
lected on employment status during follow-up from the
annual Health Service Resource use questionnaire. Unit
costs obtained from centres and from national sources
Table 2: Quality of Life questionnaires
Questionnaire Information collected YEAR
P r e - o p 1234567891 0
Rose (shortened form) Simple, evaluates angina + + + + + + + + + + +
EuroQuol-5D Short and simple, for economic evaluation + + + + + + + + + + +
SF-36 Detailed, examines eight separate dimensions + + +
Table 1: Follow-up schedule
Pre-op Intra-op Pre-discharge 6 wk clinic visit (± 1 m) Annual telephone and postal 
follow up for 10 years (± 1 m)
Baseline characteristics √ 
Clinical history √ 
Physical exam √  √ 
Medications √  √  √  √ 
LV function assessment √ 
Quality of Life 
assessment 
√  √ 
Health Service 
Resource use
√  √  √  √ 
Operation details √ 
Clinical Outcomes √  √  √ Trials 2006, 7:7 http://www.trialsjournal.com/content/7/1/7
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will be used to obtain a cost per patient. Missing data will
be handled via multiple imputations in statistical analy-
ses.
In line with the primary outcome of the trial, the main
outcome measure in the cost-effectiveness analysis will be
life years gained. These will be estimated within-trial and
over the patients' lifetime, by taking the sum of life years
obtained in each arm of the trial within the follow-up
period and modelling subsequent life expectancy, using
different assumptions about any within-trial treatment
effects continuing. The cost per quality adjusted life year
(QALY) will be calculated in the same way, using results
from the EQ-5D annual questionnaires.
The cost-effectiveness analysis will be reported in terms of
the incremental cost per life year and the incremental cost
per QALY gained. All resource use, cost, outcome and
cost-effectiveness information will be reported as the
mean per patient in each arm of the trial and the mean dif-
ference, with appropriate measures of variance. Cost-
effectiveness in sub-groups will be estimated by applying
any overall relative risk reduction and cost reduction to
different baseline absolute risk groups. Cost-effectiveness
acceptability curves and net benefit statistics will also be
reported.
Sub-group analyses
i. Diabetic vs nondiabetic
ii. Age > 70 years vs age <70 years
iii. On-pump vs off-pump
iv. Radial vs vein grafts
v. Number of grafts
vi. Left ventricular failure
Trial organisation
Trial Steering Committee (TSC)
The main role of the TSC is to monitor and supervise the
progress of the trial. The TSC membership is listed in
Table 4. Independent members are Professor Vermes
(patient lay member), Professor Sleight (Chairman and
cardiologist), Dr Stables (cardiologist), Ms Farrell (trials
advisor). The TSC will meet prior to the start of the trial
and then annually or as required thereafter.
Data Monitoring Committee (DMC)
The main role of the DMC is to consider the data from any
interim analyses and specifically to assess any safety issues
(such as unexpected serious adverse events) that occur
and report back to the TSC. The DMC membership is
listed in Table 5. All members of the DMC are independ-
ent of the trial. The DMC will meet at the start of the trial
and then annually or as required thereafter. The DMC will
be expected to develop, in agreement with the investiga-
tors, a charter outlining their responsibilities and opera-
tional details.
Clinical Event Review Committee
The Clinical Event Review Committee will review adverse
events during the study and adjudicate them to ensure the
events meet the definitions given. Each event will be inde-
pendently adjudicated by two committee members. A
third committee member will be called to adjudicate an
event if agreement is not reached by two members. These
assessments will be blind to the knowledge of which arm
of the trial the patients are in.
Study co-ordination
The study will be co-ordinated and managed by the Clin-
ical Trials and Evaluation Unit (CTEU) a dedicated clini-
cal trials department within the Royal Brompton
Hospital. In addition to providing overall project co-ordi-
nation, the CTEU will assist in preparing the final proto-
col, the investigators' manuals, design the Case Report
Forms (CRF), provide the randomisation service and
design and instigate the data management system. The
CTEU will ensure that the trial runs according to the pre-
agreed timetable, recruitment targets are met, CRFs are
completed accurately and that all aspects of the study are
performed to the highest quality. The CTEU will also assist
Table 3: ART Principal Investigators and centres
UK centres
Mr A Forsyth, Royal Sussex County Hospital, Brighton
Mr A Ritchie, Papworth Hospital, Cambridge
Mr P O'Keefe, University Hospital Of Wales, Cardiff
Mr V Zamvar, Edinburgh Royal Infirmary, Edinburgh
Mr A Cale, Castle Hill Hospital, Hull
Mr T Spyt, Glenfield Hospital, Leicester
Mr W Dihmis, Cardiothoracic Centre, Liverpool
Mr J Gaer, Harefield Hospital, London
Mr J Desai, King's College Hospital, London
Professor J Pepper, Royal Brompton Hospital, London
Mr V Chandrasekaran, St. George's Hospital, London
Mr R Hasan, Manchester Royal Infirmary, Manchester
Mr S Clark, Freeman Hospital, Newcastle
Professor D Taggart, John Radcliffe Hospital, Oxford
Mr N Briffa, Northern General Hospital, Sheffield
Australian centre
Professor B Buxton, Austin & Repatriation Medical Centre, Victoria
Polish centres
Professor A Bochenek, 1st Dept of Cardiac Surgery, Katowice
Professor S Wos, 2nd Dept of Cardiac Surgery, Katowice
Dr R Pawlaczyk, Medical University of Gdansk, Gdansk
Brazilian centre
Dr F Moraes, Heart Institute of Pernambuco, RecifeTrials 2006, 7:7 http://www.trialsjournal.com/content/7/1/7
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in the training of investigators and co-ordinators at the
start-up of the study and for performing monitoring pro-
cedures throughout.
The trial management team from CTEU will meet the
Chief Investigator weekly by conference call.
Centres
Study sites
The list of participating centres is given in Table 3. Each
centre will be paid a pro-rata sum of 1.0 FTE for years 1–
2, 0.5 FTE for year 3 and 0.2 FTE for years 4–10, to help
support a study co-ordinator.
Study site co-ordinators will be responsible for screening
patients (and recording the data on a screening log),
enrolling patients into the trial, providing a contact point
for patients, liasing with CTEU, completing CRFs, ensur-
ing annual questionnaires are sent and processed, record-
ing adverse events, ensuring forms are sent to CTEU and
that all edit queries are resolved.
Data collection
Each centre will be provided with a Protocol, Manual of
Operations, questionnaires and patient CRFs. Data will be
recorded onto two part NCR CRFs and the top copy sent
to the CTEU at the times specified. Specific adverse event
forms for death, myocardial infarction, major bleed, cere-
brovascular accident, revascularisation and other serious
adverse events (ie. other events that require or prolong
hospitalisation) are provided. Centres are required to
complete these adverse event forms and fax to the CTEU
within 72 hours of their knowledge of the event.
Investigators' responsibilities
Surgeons must have completed a minimum of 50 BIMA
operations before commencing on the study. Investigators
must ensure that Local Ethics Committee approval has
been obtained as well as Agreements signed off by their
Institution prior to the start of the study.
Investigators are required to ensure compliance to the
protocol, CRFs and Manual of Operations. Investigators
are required to allow access to study documentation or
source data on request for monitoring visits and audits
performed by the CTEU or any regulatory authorities.
Training
Pre-study training visit
Before the study commences each centre will receive a
training visit by CTEU. These visits will ensure that per-
sonnel at each site (including principal investigators, co-
investigators and the study site co-ordinator) fully under-
stand the protocol, CRF and the practical procedures for
the study.
Monitoring visits
At regular intervals during the study CTEU will perform
monitoring visits to each centre. The purpose of these vis-
its is to ensure compliance to the protocol and that ethical
and regulatory guidelines are met. Source data verification
and checking of essential documents will be performed.
Monitoring visits also provide an opportunity for further
training if required (eg new staff). Central review of study
data will also be performed throughout the study.
Close-out visit
At the end of the study each centre will receive a site visit
from CTEU to resolve any outstanding edit queries or
adverse events and to verify the correct storage of study
documentation.
Table 4: Trial Steering Committee membership
Name Trial Role Title Affiliation
Professor G Vermes Patient Lay Member Emeritus Professor of Hebrew 
Studies
Oxford
Professor D Altman Statistician Professor of Statistics in Medicine, Oxford
Professor J Dark Lead Surgeon Professor of Cardiac Surgery Newcastle
Ms B Farrell Trials Advisor Co-Director, Resource Centre for 
Randomised Trials
Oxford
Dr M Flather Co-Principal Investigator Director, CTEU, Royal Brompton 
Hospital
London
Professor A Gray Health Economist Professor of Health Economics Oxford
Professor J Pepper Lead Surgeon Professor of Cardiac Surgery London
Professor P Sleight CHAIRMAN Emeritus Professor Cardiology Oxford
Professor K Channon Cardiologist Professor of Cardiovascular 
Surgery
Oxford
Dr R Stables Independent Cardiologist Consultant Cardiologist Liverpool
Professor D Taggart Chief Investigator Consultant Cardiac Surgeon OxfordTrials 2006, 7:7 http://www.trialsjournal.com/content/7/1/7
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Ethics
This study will conform to the MRC Guidelines for Good
Clinical Practice in Clinical Trials (1998) [30] and the
Declaration of Helsinki guidelines (2004) [31]. The study
protocol will be submitted to the appropriate Ethical
Review Committee in each country participating in the
study and approval will be obtained before the study com-
mences.
Informed consent
"Informed consent" requires individual discussion with
the patient about the nature of the procedures to be con-
ducted in a language that is easy to comprehend. The
patient should fully understand that he/she might be allo-
cated to either the SIMA or the BIMA group. The patient
should also understand that his/her refusal to participate
in the study will not affect the quality of subsequent med-
ical care. It is recommended that, if possible, the patient
has at least 24 hours to think about participation and dis-
cussing with family or friends before signing the consent
form.
Before any trial-related procedures may be performed,
informed consent must be obtained from the patient by
the investigator by means of a signed declaration. The
investigator must sign in the CRF to confirm that
informed consent was obtained and store the original of
the signed declaration of consent in the patient's notes. A
copy should be given to the patient and a copy filed in the
patient's CRF.
Publication policy
The results from the trial will be submitted for publication
in a major journal irrespective of the outcome. The Trial
Steering Committee will be responsible for approval of all
manuscripts arising from the study prior to submission
for publication. Sub-studies of centre-specific data may
only be carried out with the knowledge and approval of
the Trial Steering Committee.
Authorship of presentations and reports related to the
study will be in the name of the collaborative group. The
final follow-up study results paper will name local co-
ordinators as well as those involved in central co-ordina-
tion and trial management. Co-ordinators who provided
data will be named. Certificates of collaboration will be
provided to those who have made a substantial contribu-
tion but whose name is not on the final report.
Papers on other aspects of the study will be published
with those who made substantive contributions being
named as authors. These papers will make appropriate
acknowledgement of the contribution of the collabora-
tivegroup. At the end of the study, patients will be able to
request a copy of the results of the study from the investi-
gator at that site.
Proposed timetable for ART study
Jun 2004 Grant awarded by MRC & BHF - Recruitment
starts
Jun 2007 Recruitment completed
2009 First patient completes 5 years
2012 Last patient completes 5 years  - Analysis and publi-
cation of 5 year data
2014 First patient completes 10 years
2017 Last patient completes 10 years
2017/8 Publication of 10 year data
Discussion
The ART study is one of the first randomised trials to eval-
uate the effects on survival and other clinical outcomes of
SIMA grafting versus BIMA grafting, and will help to estab-
lish the best approach for patients requiring CABG sur-
gery.
Abbreviations
CABG: coronary artery bypass graft
IMA: internal mammary artery
SIMA: single internal mammary artery
BIMA: bilateral internal mammary artery
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OPCAB: off-pump coronary artery bypass
LIMA: left internal mammary artery
RIMA: right internal mammary artery
LAD: left anterior descending artery
OM: obtuse marginal branch of the circumflex coronary
artery
CRF: case report form
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